Positive Topline Results for SEQUOIA-HCM Trial in OHCM

 Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.
Medscape Medical News

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart